PMI's IQOS Revenue Surpasses Marlboro, Aiming for 100B sales

Oct.11.2024
PMI's IQOS Revenue Surpasses Marlboro, Aiming for 100B sales
According to El Economista on October 9, Philip Morris International's IQOS device surpasses Marlboro in revenue, reaching $10 billion.

According to El Economista on October 9th, 38% of Philip Morris International's (PMI) global net income comes from non-cigarette alternative products. Revenue from their heated tobacco device "IQOS" has surpassed that of their most important cigarette brand Marlboro for the first time, with IQOS projected to exceed $10 billion in global sales by 2023.


It is reported that PMI's cigarette alternative products have now entered over 90 markets worldwide, with a total investment of $14 billion and a team of 1,500 people working on innovation.


The company's CEO, Jacek Olczak, stated during a media briefing in Neuchâtel, Switzerland, that...


The figures we have achieved are remarkable. Despite realizing that the market is developing faster than expected, there is still a long way to go.


Eujia further emphasized that it took IQOS 10 years to achieve sales of $10 billion, while Meta took 9 years, Amazon took 12 years, and Tesla took 14 years.


Philip Morris International (PMI) believes that there are 1.1 billion smokers worldwide and that the current measures being implemented are not effective enough. The IQOS device was initially launched in Milan, Italy, and Nagoya, Japan, and now has 30.8 million users. Oscar Jager stated, "In some countries, such as Japan, alternatives have already surpassed traditional cigarettes." He further emphasized that the company will continue to invest in new innovations to accelerate the transformation and aims to achieve 66% of revenue from alternatives by 2030.


However, the spokesperson acknowledged that due to insufficient information, many countries are skeptical of alternative products.


Some activists claim that these products are just as harmful as cigarettes, but we have proven that this is not true. People need to make informed decisions, as there is no scientific research indicating that these products are exactly the same as cigarettes.


Ouyaje criticized some government's strict regulation.


They refuse to listen to our advice because we are a tobacco company, but all of this is based on scientific data - nicotine does not cause cancer. This situation is similar to the COVID-19 vaccine, where some people are unwilling to get vaccinated despite scientific evidence.


He also stated that the World Health Organization "even refused to respond to our information".


Notice

1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.

2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.

3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.

Copyright

This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.

This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.

The Proliferation of Illegal E-cigarette Sales in India
The Proliferation of Illegal E-cigarette Sales in India
Despite a ban, illegal e-cigarette sales persist in India through online and offline channels, leading to widespread availability.
Apr.08 by 2FIRSTS.ai
Aspire secures exclusive deal with Korean distributor to expand market reach in South Korea
Aspire secures exclusive deal with Korean distributor to expand market reach in South Korea
South Korean e-cigarette device supplier InnoIT has become the exclusive distributor for the Aspire brand in South Korea. The company plans to roll out Aspire products across convenience stores and major retail outlets in the country, while also preparing to promote its own brand, Eto.
Oct.29 by 2FIRSTS.ai
Dutch Health Experts Call for Tougher Anti-Smoking Policies
Dutch Health Experts Call for Tougher Anti-Smoking Policies
Dutch health experts call for stronger anti-tobacco policies as one-third of young people still smoke.
Sep.05 by 2FIRSTS.ai
Joint Report to Participate in Government Consultation on Youth E-cigarettes
Joint Report to Participate in Government Consultation on Youth E-cigarettes
Bromsgrovestandard reports that Bromsgrove District Council members plan to join government consultations on tackling youth e-cigarette use.
Regulations
Nov.03 by 2FIRSTS.ai
KT&G New Kanchin Factory Donates 20 Million Korean Won for Residence Improvement
KT&G New Kanchin Factory Donates 20 Million Korean Won for Residence Improvement
KT&G's new factory in South Korea has donated 20 million Korean won to support the "Improving Residential Environment" project for disabled individuals.
Business
Sep.22 by 2FIRSTS.ai
Nicotine pouches: unregulated and widely available in the UK
Nicotine pouches: unregulated and widely available in the UK
Nicotine pouches are small bags of nicotine placed under the lip, sold in UK supermarkets without strict regulations.
Nov.01 by 2FIRSTS.ai